The role of adiponectin in development and progression of cardiovascular diseases

Kardiologiya

Volumn 49, Issue 1, 2009, Pages 51-58

  Kobalava, Zh D ^a   Villewalde, S V ^a   Isikova, Kh V ^a  

^a PEOPLES FRIENDSHIP UNIVERSITY OF RUSSIA   (Russian Federation)

Author keywords

Adipocytokines; Adiponectin; Arterial hypertension; Metabolic syndrome

Indexed keywords

ADIPONECTIN;

ADIPOSE TISSUE; ANIMAL; BLOOD; CARDIOVASCULAR DISEASE; DISEASE COURSE; HUMAN; METABOLISM; PROGNOSIS; REVIEW;

ADIPONECTIN; ADIPOSE TISSUE; ANIMALS; CARDIOVASCULAR DISEASES; DISEASE PROGRESSION; HUMANS; PROGNOSIS;

EID: 65649114028     PISSN: 00229040     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (123)

1. Mokdad A.H., Serdula M.K., Dietz W.H. et al. The spread of the obesity epidemic in the United States, 1991-1998. JAMA 1999;282:1519-1522. (Pubitemid 29504044)
2. Scherer P.E. Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes 2006;55:1537-1545. (Pubitemid 44324105)
3. Berg A.H., Scherer P.E. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 2005;96:939-949. (Pubitemid 40712793)
4. Goldstein B.J., Scalia R. Adiponectin: a novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab 2004;89:2563-2568. (Pubitemid 38766332)
5. Hopkins TA., Ouchi N., Shibata R., Walsh K. Adiponectin actions in the cardiovascular system. Cardiovasc Res 2007;74:11-18. (Pubitemid 46366942)
6. Scherer P.E., Williams S., Fogliano M. et al. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995;270:26746-26749.
7. Hu E., Liang P., Spiegelman B.M. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 1996;271:10697-10703. (Pubitemid 26145805)
8. Nakano Y., Tobe T., Choi-Miura N.H. et al. Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem (Tokyo) 1996;120:803-812. (Pubitemid 26385421)
9. Maeda K., Okubo K., Shimomura I. et al. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM I (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 1996;221:286-289. (Pubitemid 26136463)
10. Kadowaki T., Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005;26:439-451. (Pubitemid 40686653)
11. Pajvani U.B., Hawkins M., Combs T.P. et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedionemediated improvement in insulin sensitivity. J Biol Chem 2004;279:12152-12162. (Pubitemid 38445780)
12. Tonelli J., Li W., Kishore P. et al. Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes. Diabetes 2004;53:1621-1629. (Pubitemid 38697679)
13. Lara-Castro C., Luo N., Wallace P. et al. Adiponectin multimeric complexes and the metabolic syndrome trait cluster. Diabetes 2006;55:249-259. (Pubitemid 43343322)
14. Yamauchi T., Kamon J., Ito Y. et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003;423:762-769. (Pubitemid 36735700)
15. Rasmussen U.S., Lihn A.S., Pedersen S.B. et al. Adiponectin receptors in human adipose tissue: effects of obesity, weight loss, and fat depots. Obesity 2006;14:28-35. (Pubitemid 46214772)
16. Debard C., Laville M., Berbe V. et al. Expression of key genes of fatty and oxidation, including adiponectin receptors in skeletal muscle of type 2 diabetic patients. Diabetologia 2004;47:917-925. (Pubitemid 38757006)
17. Nishizawa H., Shimomura I., Kishida K. et al. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 2002; 51: 2734-2741. (Pubitemid 34970926)
18. Iwashima Y., Katsuya T., Ishikawa K. et al. Association of hypoadiponectinemia with smoking habit in men. Hypertension 2005;45:1094-1100. (Pubitemid 40770311)
19. Iwashima Y., Katsuya T., Ishikawa K. et al. Hypoadiponectinemia is an Independent Risk Factor for Hypertension. Hypertension 2004;43:1318-1323. (Pubitemid 38691756)
20. Arita J., Kihara S., Ouchi N. et al. Paradoxal decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999;257:79-83. (Pubitemid 29299050)
21. Hotta K., Funahashi T., Arita Y. et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000;20:1595-1599. (Pubitemid 30353893)
22. Ouchi N., Kihara S., Arita Y. et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999;100:2473-2476. (Pubitemid 30005109)
23. Kumada M., Kihara S., Sumitsuji S. et al. Coronary artery disease. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003;23:85-89. (Pubitemid 36091630)
24. Zoccali C., Mallamaci F., Tripepi G. et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 2002;13:134-141. (Pubitemid 34042020)
25. Imagawa A., Funahashi T., Nakamura T. et al. Elevated serum concentration of adipose-derived, adiponectin, in patients with type 1 diabetes. Diabetes Care 2002;25:1665-1666.
26. Weisberg S.P., McCann D., Desai M. et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112:1796-1808. (Pubitemid 38063703)
27. Fain J.N., Bahouth S. W., Madan A.K. TNF alpha release by nonfat cells of human adipose tissue. Int J Obes Relat Metab Disord 2004;28:616-622. (Pubitemid 38491155)
28. Wiecek A., Adamczak M., Chudek J. Adiponectin - an adipokine with unique metabolic properties. Nephrol Dial Transplant 2007;22:981-988. (Pubitemid 46523405)
29. Wang B., Trayhurn P. Acute and prolonged effects of TNF-alpha on the expression and secretion of inflammation-related adipokines by human adipocytes differentiated in culture. Pflugers Arch 2006;452:418-427. (Pubitemid 43962051)
30. Matsubara M., Maruoka S., Katayose S. Inverse relationship between plasma adiponectin and leptin concentrations in normal-weight and obese women. Eur J Endocrinol 2002;147:173-180.
31. Yamomoto Y., Hiroso H., Saito I. et al. Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population. Clinical Sciences 2002;103:137-142.
32. Diez J., Iglesias P. The role of the novel adipocite-derived hormone adiponectin in human disease. European Journal of Endocrinology 2003; 148:293-300. (Pubitemid 36410714)
33. Hara K., Horikoshi M., Yamauchi T. et al. Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care 2006;29:1357-1362. (Pubitemid 44125935)
34. Waki H, Yamauchi T., Kamon J. et al. Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J Biol Chem 2003;278:40352-40363. (Pubitemid 37248604)
35. Hotta K, Funahashi T., Bodkin N.L. et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during progression to type 2 diabetes in rhesus monkeys. Diabetes 2001;50:1126-1133. (Pubitemid 32374544)
36. Lindsay R.S., Funahashi T., Hanson R. et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002;360:57-58. (Pubitemid 34756495)
37. Lihn A.S., Ostergard T., Nyholm B. et al. Adiponectin mRNA expression in subcutaneous adipose tissue is reduced in first-degree relatives of type 2 diabetic patients. Am J Physiology. Endocrinology and Metabolism 2003;284:443-448.
38. Grossi G. Sympathetic overdrive and cardiovascular risk in the metabolic syndrome. Hypertens Res. 2006;29:839-847.
39. Imai J., Katagiri H., Yamada T. et al. Cold exposure suppresses serum adiponectin levels through sympathetic nerve activation in mice. Obesity (Silver Spring). 2006;14:1132-1141. (Pubitemid 46219679)
40. Spranger J., Kroke A., Mohlig M. et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003;361:226-228. (Pubitemid 36126226)
41. Snijder M.B., Heine R.J., Seidell J.C. et al. Associations of adiponectin levels with incident impaired glucose metabolism and type 2 diabetes in older men and women: the Hoorn Study. Diabetes Care 2006;29:2498-2503. (Pubitemid 44912259)
42. Ohashi K., Kihara S., Ouchi N. et al. Adiponectin replenishment ameliorates obesity-related hypertension. Hypertension. 2006;47:1108-1116. (Pubitemid 44289168)
43. Yamauchi T., Nio Y., Maki T. et al. Targeted disruption of AdipoRl and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 2007;13:332-339. (Pubitemid 46376688)
44. Mao X., Kikani C.K., Riojas R.A. et al. APPL1 binds to adiponectin receptors and mediates adiponectin signalling and function. Nat Cell Biol 2006;8:516-523.
45. Mallamaci F., Zoccali C., Cuzzola F. et al. Adiponectin in essential hypertension. J Nephrol 2002;15:507-511. (Pubitemid 35396514)
46. Adamczak M., Wiecek A., Funahashi T. et al. Decreased plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens 2003;16:72-75. (Pubitemid 36078595)
47. Kazumi T., Kawaguchi A., Sakai K. et al. Young men with high-normal blood pressure have lower serum adiponectin, smaller LDL size, and higher elevated heart rate than those with optimal blood pressure. Diabetes Care 2002;25:971-976. (Pubitemid 41110480)
48. Furuhashi M., Ura N., Hbhiura K. et al. Blockade of renin-angiotensin system increases adiponectin concentration in patients with essential hypertension. Hypertension 2003;42:76-81. (Pubitemid 36842239)
49. Ouchi N., Ohishi M., Kihara S. et al. Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 2003;42:231-234. (Pubitemid 37093465)
50. Ouedraogo R., Gong Y., Berzins B. et al. Adiponectin deficiency increases leukocyte-endothelium interactions via upregulation of endothelial cell adhesion molecules in vivo. J Clin Invest 2007;117:1718-1726. (Pubitemid 46871356)
51. Tan K. C., Xu A., Chow W.S. et al. Hypoadiponectinemia is associated with impaired endotheliumdependent vasodilation. J Clin Endocrinol Metab 2004;89:765-769. (Pubitemid 38269891)
52. Hattori Y., Suzuki M., Hattori S., Kasai K. Globular adiponectin upregulates nitric oxide production in vascular endothelial cells. Diabetologia 2003;46:1543-1549. (Pubitemid 37518575)
53. Chen H., Montagnani M., Funahashi T. et al. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 2003;278:45021-45026. (Pubitemid 37377262)
54. Cheng K.K., Lam K.S., Wang Y. et al. Adiponectin-induced endothelial nitric oxide synthase activation and nitric oxide production are mediated by APPL1 in endothelial cells. Diabetes 2007;56:1387-1394. (Pubitemid 46715600)
55. Fasshauer M., Klein J., Neumann S. et al. Adiponectin gene expression is inhibired by beta-adrenergic stimulation via protein kinase A in 3T3-L1 adipocytes. FEBS Lett 2001;507:142-146. (Pubitemid 33001531)
56. Masslera F., Btoch-Faure M., Ceiler D. et al. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J 2001;15:2727-2729.
57. Liao Y., Takashima S., Maeda N. et al. Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism. Cardiovasc Res 2005;67:705-713. (Pubitemid 41033366)
58. Shibata R., Ouchi N., Ito M. et al. Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med 2004;10:1384-1389. (Pubitemid 40022722)
59. Maeda T., Taniguchi S., Sasaki H. et al. Relationship between plasma adiponectin and cardiac function in patients with end-stage renal disease. J Hypertens 2006;24:302.
60. Adamczpk M., Mach A., Kolonko A. et al. Does relationship exist between plasma adiponectin concentration and left ventricular mass in kidney transplant patients? Nephrol Dial Transplant 2006;21:276.
61. Adamczak M., Rzepka E., Chudek J., Wicek A. Ageing and plasma adiponectin concentration in apparently healthy males and females. Clin Endocrinol 2005;62:114-118. (Pubitemid 40175291)
62. Becker B., Kronenberg F., Kielstein J. T. et al. Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol 2005;16:1091-1098. (Pubitemid 41710320)
63. Saraheimo M., Forsblom C., Fagerudd J. et al. Serum adiponectin is increased in type 1 diabetic patients with nephropathy. Diabetes Care 2005;28:1410-1414. (Pubitemid 40756705)
64. Schalkwijk C.G., Chaturvedi N., Schram M.T. et al. EURODIAB Prospective Complications Study Group. Adiponectin is inversely associated with renal function in type 1 diabetic patients. J Clin Endocrinol Metab 2006;91:129-135. (Pubitemid 43069128)
65. Adamczak M., Szotowska M., Chudek J. et al. Plasma adiponectin concentration in patients after successful kidney transplantation 6 a single centre, observational study. Clinical Nephrology 2005.
66. Ignacy W., Chudek J., Adamczak M. et al. Reciprocal association of plasma adiponectin and serum C-reactive protein concentration in haemodialysis patients with end-stage kidney disease 6 a follow-up study. Nephron Clin Pract 2005;101:18-24.
67. Marchlewska A., Stenvlnkel P., Lindholm B. et al. Reduced gene expression of adiponectin in fat tissue from patients with end-stage renal disease. Kidney Int 2004;66:46-50. (Pubitemid 38870080)
68. Chudek J., Adamczak M., Karkoszka H. et al. Plasma adiponectin concentration before and after successful kidney transplantation. Transplant Proc 2003;35:2186-2189. (Pubitemid 37194359)
69. Engeli S., Feldpausch M., Gorzelniak K. et al. Association between adiponectin and mediators of inflammation in obese women. Diabetes 2003;52:942-947. (Pubitemid 36384264)
70. Lee C.T., Lee C.H., Su Y. et al. The relationship between inflammatory markers, leptin and adiponectin in chronic hemodialysis patients. Int J Artif Organs 2004;27:835-841. (Pubitemid 40484595)
71. Fasshauer M., Kralisch S., Klier M. et al. Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2003;301:1045-1050. (Pubitemid 36279218)
72. Pischon T., Girman C.J., Hotamisligil O.S. et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004; 14:1730-1737. (Pubitemid 38489895)
73. Schulze M.B., Shai I., Rimm E.B. et al. Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes 2005;54:534-539.
74. Cavusoglu E., Ruwende C., Chopra V. et al. Adiponectin is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction in patients presenting with chest pain. Eur Heart J 2006;27:2300-2309. (Pubitemid 44453573)
75. Iwashima Y., Horio T., Suzuki Y. et al. Adiponectin and renal function, and risk of cardiovascular disease. J Hypertens 2006;24:354.
76. Menon V., Li L., Wang X. et al. Adiponectin and mortality in patients with chronic kidney disease. J Am Soc Nephrol 2006;16:1091-1098.
77. Go A.S., Chertow G.M., Fan D. et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-1305.
78. Samak M.J., Levey A.S., Schoohverth A.C. et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003;108:2154-2169. (Pubitemid 37337595)
79. von Eynatten M., Schneider J.G., Humpert P.M. et al. Serum adiponectin level are an independent predictor of the extent of coronary artery disease in men. J Am Coll Cardiol 2006;46:2124-2126.
80. Otsuka F., Sugiyama S., Kojima S. et al. Plasma adiponectin levels are associated with coronary lesion complexity in men with coronary artery disease. J Am Coll Cardiol 2006;48:1155-1162. (Pubitemid 44345143)
81. Nilsson PM, Engstrom G., Hedblad B. et al. Plasma adiponectin levels in relation to carotid intima media thickness and markers of insulin resistance. Arterioscler Thromb Vasc Biol 2006;26:2758-2762.
82. Suganami T., Nishida J., Ogawa Y. A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor alpha. Arterioscler Thromb Vasc Biol 2005;25:2062-2068. (Pubitemid 41416301)
83. Ouchi N., Kihara S., Arita Y. et al. Adiponectin, adipocyte-derived plasma protein, inhibits endothelial NF-κβ signaling through a cAMP-dependent pathway. Circulation 2000;102:1296-1301.
84. Ouchi N., Kihara S., Arita Y. et al. Adipocyt-derived plasma protein, adiponectin, suppress lipid accumulation and class A receptor expression in human monocyte-derived macrophages. Circulation 2001;103:1057-1063. (Pubitemid 32200177)
85. Motoshima H., Wu X., Mahadev K, Goldstein B.J. Adiponectin suppresses proliferation and superoxide generation and enhances eNOS activity in endothelial cells treated with oxidized LDL. Biochem Biophys Res Commun 2004;315:264-271. (Pubitemid 38183103)
86. Magalang U.J., Rajappan R., Hunter M.G. et al. Adiponectin inhibits superoxide generation by human neutrophils. Antioxid Redox Signal 2006;8:2179-2186. (Pubitemid 46489642)
87. Arita Y., Kihara S., Ouchi N. et al. Adipocyte-derived plasma protein, adiponectin, acts as a plateletóderived growth-factor-BB-binding protein and regulates growth factor-induced common post-receptor signal in vascular smooth muscle cell. Circulation 2002;105:2893-2898. (Pubitemid 34666104)
88. Wang Y., Lam K.S., Xu J. Y. et al. Adiponectin inhibits cell proliferation by interacting with several growth factors in an oligomerization-dependent manner. J Biol Chem 2005;280:18341-18347. (Pubitemid 41389081)
89. Kobayashi H., Ouchi N., Kihara S. et al. Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Cli Res 2004;94:27-31.
90. Kumada M., Kihara S., Ouchi N. et al. Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation 2004;109:2046-2049. (Pubitemid 38620209)
91. Kadowaki T., Yamauchi T., Kubota N. et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and metabolic syndrome. J Clin Invest 2006;116:1784-1792. (Pubitemid 44033298)
92. Yamauchi T., Kamon J., Waki H. et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001;7:941-946. (Pubitemid 32756432)
93. Ceddia R.B., Somwar R., Maida A. et al. Globular adiponectin increases GLUT4 translocation and glucose uptake but reduces glycogen synthesis in rat skeletal muscle cells. Diabetologia 2005;48:132-139. (Pubitemid 40174665)
94. Fu Y, Luo N., Klein R.L., Garvey W.T. Adiponectin promotes adipocyte differentiation, insulin sensitivity, and lipid accumulation. J Lipid Res 2005;46:1369-1379. (Pubitemid 43109800)
95. Stefan N., Vozarova B., Funahashi T. et al. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes 2002;51:1884-1888. (Pubitemid 34564302)
96. Wang Z.V., Scherer E.P. Adiponectin, Cardiovascular Function, and Hypertension Hypertension 2008;51;8-14.
97. Yamauchi T., Kamon J., Minokoshi Y. et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nature Medicine 2002;8:1288-1295. (Pubitemid 35373562)
98. Yang W.S., Lee W.J., Funahashi T. et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 2001;86:3815-3819. (Pubitemid 32755982)
99. Esposito K., Pontillo A., Di Palo C. et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003;289:1799-1804. (Pubitemid 37430249)
100. Valsamakis G., McTeman P.G., Chetty R. et al. Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines. Metabolism 2004;53:430-434. (Pubitemid 38419183)
101. Yu J.G., Javorschi S., Hevener A.L. et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 2002;51:2968-2974.
102. Hirose H., Kaqviai T., Yamamoto Y. et al. Effects of pioglitasone on metabolic parameters, body fat distribution and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metab Clin Exp 2002;51:314-317. (Pubitemid 34232632)
103. Phillips S.A., Ciaraldi T.P., Kong A.P. et al. Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes 2003;52:667-674. (Pubitemid 36323573)
104. Yang W.S., Jeng C.Y., Wu T.J. et al. Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 2002;25:376-380.
105. Bobbert T., Rochlitz H, Wegewitz U. et al. Changes of adiponectin oligomer composition by moderate weight reduction. Diabetes 2005;54:2712-2719. (Pubitemid 41233594)
106. Koh K., Quon M., Han S. et al. Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes. Hypertension 2005;45:1088-1093. (Pubitemid 40770310)
107. Koh K., Quon M., Han S. et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 2004;110:3687-3692. (Pubitemid 39665258)
108. Koh K., Quon M., Han S. et al. Anti-inflammatory and metabolic effects of candesartan in hypertensive patients. Int J Cardiol 2005;108:96-100.
109. Shmieder R., Schlaich M., Mimran A. et al. The cytokine adiponectin is disparately influenced by telmisartan and ramipril in type 2 diabetes. J Hypertens 2006;24:225.
110. Fogari R., Derosa G., Mugellini A. et al. Effect of valsartan and eprosartan on adiponectin, leptin and insulin sensitivity in hypertensive obese patients. J Hypertens 2006;24:258.
111. Nowak E., Adamczak M., Wicek A. Blockade of sympathetic nervous system activity by rilmenidine increases plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens 2005;18:1470-1475. (Pubitemid 41566678)
112. Koh K., Quon M., Han S. et al. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. J Am Coll Cardiol 2005;45:1649-1653. (Pubitemid 40704501)
113. Despres J.P., Golay A., Sjostrom L. Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005;353:2121-2134. (Pubitemid 41653104)
114. Wicek A., Piecha G., Chudek J., Adamczak M. Influence of different antihypertensive drugs on plasma adiponectin concentration in patients with essential hypertension. J Hypertens 2006;24:356.
115. Ran J., Hirano T., Fukui T. et al. Angiotensin II infusion decreases plasma adiponectin level via its type 1 receptor in rats: an implication for hypertension-related insulin resistance. Metabolism 2006;55:478-488.
116. Laursen J.B., Rajagopalan S., Galis Z. et al. Role of superoxide in angiotensin 11-induced but not catecholamineinduced hypertension. Circulation 1997;95:588-593. (Pubitemid 27063033)
117. Furukawa S., Fujita T., Shimabukuro M. et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004;114:1752-1761. (Pubitemid 40385531)
118. Dahlof B., Devereux R.B., Kjetdsen S.E. et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003. (Pubitemid 34286536)
119. Julius S., Kjeldsen S.E., Weber M. et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-2031. (Pubitemid 38781102)
120. Benson S.C., Pershadsingh H.A., Ho C.I. et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgammamodulating activity. Hypertension 2004;43:993-1002. (Pubitemid 38579904)
121. Schupp M., Janke J., Clasen R. et al. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004; 109:2054-2057. (Pubitemid 38620211)
122. Clasen R., Schupp M., Foryst-Ludwig A. et al. PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension 2005;46:137-143. (Pubitemid 40946504)
123. Kmtscher U., Unger T. Vascular protection in diabetes: a pharmacological view of angiotensin II type 1 receptor blockers. Acta Diabetol 2005;42:26-32.